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Innate Lymphoid Cells in the Skin
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Innate lymphoid cells (ILCs) are part of a heteroge-
neous family of innate immune cells with newly
identified roles in mediating immunity, tissue home-
ostasis, and pathologic inflammation. Here, we review
recent studies delineating the roles of ILCs in the
pathogenesis of multiple inflammatory skin disorders
and their unique effector functions. Finally, we address
how these studies have informed our understanding
of the regulation of ILCs and the therapeutic potential
of targeting these cells in the context of skin
inflammation.
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INTRODUCTION
Classically, it is believed that adaptive helper T cells underlie
the pathogenesis of multiple inflammatory skin disorders such
as atopic dermatitis (AD; Bieber, 2008) and psoriasis (Nestle
et al., 2009). Unique cytokine profiles distinguish TH cells into
different subsets and define their effector functions. For
example, T helper type 2 (TH2) cells that produce hallmark
type 2 cytokines IL-4, IL-5, and IL-13 are believed to underlie
the pathogenesis of AD (Brandt and Sivaprasad, 2011). In
contrast, T helper type 17 (TH17) cells that produce IL-17 and
IL-22 contribute to the development and progression of
psoriasis (Lowes et al., 2014). Traditionally, immuno-
suppressive therapeutics for the treatment of AD (e.g.,
calcineurin inhibitors) and psoriasis (e.g., methotrexate) are
thought to broadly inhibit the function of these TH cell subsets.
However, recent studies suggest that previously unrecognized
innate immune cells may regulate TH cells in the skin and
have direct contributions to the development of pathologic
skin inflammation. Specifically, innate lymphoid cells (ILCs)
have emerged as key players in the pathogenesis of multiple
inflammatory skin disorders. This review will focus on the
recent advances in our understanding of how ILCs drive skin
inflammation and how they may differentially respond to
tissue-specific cytokines and factors. We highlight recent
studies that reveal how ILCs are regulated and discuss the
therapeutic potential of targeting ILCs in the context of skin
inflammation.
DEFINITION OF INNATE LYMPHOID CELL SUBSETS
ILCs are part of a family of innate immune cells that are
derived from a common lymphoid progenitor, and their
development is partially or completely dependent on the
common g-chain (gc or CD132), IL-7, Notch, and the trans-
cription factor inhibitor of DNA binding 2 (Mjosberg and
Eidsmo, 2014). More recent studies indicate that multiple ILC
lineages are also dependent on the transcriptional repressor
PLZF, whereas others (e.g., natural killer cells and lymphoid
tissue inducers) are not (Constantinides et al., 2014). Further,
all ILC subsets have also been shown to arise from a common
lineage-negative inhibitor of DNA binding 2þ CD127þ
CD25 a4b7þ c-Kitþ precursor (Constantinides et al.,
2014; Klose et al., 2014). ILCs are currently categorized into
three distinct populations on the basis of their developmental
requirements, transcription factor expression profile, and/or
expression of effector cytokines (Figure 1): group 1 ILCs
(ILC1s) are T-bet-dependent IFN-g- and TNF-a-producing ILCs;
RORa-dependent, TCF-1-dependent, and GATA3-expressing
group 2 ILCs (ILC2s) produce IL-4, IL-5, and IL-13; and RORgt-
dependent group 3 ILCs (ILC3s) produce IL-17A and/or IL-22
(Sonnenberg et al., 2013). These ILC groups are analogous to
the previously described IFN-g and TNF-a-producing TH1,
IL-4-, IL-5- and IL-13-producing TH2 and IL-17- and IL-22-
producing TH17 CD4
þ TH cell subsets. However, although
ILCs appear to have parallel functions to adaptive CD4þ
T cells, they are unique in that they respond to innate signals
in the absence of antigen-specificity, and they have distinct
phenotypic and functional profiles.
Although similar to TH cell subsets in their cytokine profile,
ILCs are distinguished from the common cell lineages in that
they do not express cell lineage markers associated with T
cells, B cells, dendritic cells, macrophages, and granulocytes
but express CD25 (IL-2Ra), CD90 (Thy1 Ag), and CD127 (IL-
7Ra, Spits and Cupedo, 2012). Further, ILC2s can be readily
identified by their expression of the receptor for IL-33 (IL-33R
or T1/ST2 in mice or ST2 in humans). Different subsets of ILCs
promote either tissue homeostasis or detrimental inflammatory
processes at multiple epithelial barrier surfaces. Further, these
cells have been implicated in a variety of different disease
states including allergy, autoimmunity, cancer, infection, and
obesity (Sonnenberg and Artis, 2012; Hams et al., 2013; Kim
et al., 2013b; Molofsky et al., 2013; Nussbaum et al., 2013).
The roles of ILCs in various disease states and at other barrier
surfaces have been covered extensively elsewhere (Monticelli
et al., 2012; Sonnenberg and Artis, 2012; Fuchs and Colonna,
2013; Hepworth et al., 2013; Locksley and Fahy, 2014).
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However, the diverse functional properties of ILCs in the skin
remain less well defined. Therefore, in this review we will
focus primarily on the emerging role of ILCs in skin health and
disease. First, we will introduce ILC2s given that multiple
groups have defined their contribution to AD. Second, we will
highlight recent studies identifying skin ILC3s and their role in
psoriasis. Finally, we will briefly outline the function of ILC1s
and their potential role in skin inflammation.
ILC2s AND AD
ILC2s were originally identified in the gut and associated
lymphoid tissues and found to contribute to immunity to
helminth parasites in the absence of the adaptive immune
system (Fort et al., 2001; Schmitz et al., 2005; Fallon et al.,
2006; Moro et al., 2010; Neill et al., 2010; Price et al., 2010).
In addition to being distinguished by their expression of the
effector type 2 cytokines IL-5 and IL-13, ILC2s also express IL-
33R (Kim et al., 2013b). Subsequent studies showed that ILC2s
have key roles in airway hyperreactivity (Chang et al., 2011)
and epithelial tissue repair in the lung (Monticelli et al., 2011)
in mice and chronic rhinosinusitis in humans (Mjosberg et al.,
2011, 2012). These early studies demonstrated that ILC2s were
predominantly regulated by the epithelial cell–derived cyto-
kines IL-25 and IL-33 (Monticelli et al., 2012).
When ILC2s were first identified in both murine (Kim et al.,
2013a; Roediger et al., 2013) and human skin, they were also
found to be highly enriched in the lesional skin of patients
with AD (Kim et al., 2013a). Adaptive CD4þ TH2 cells that
produce the effector type 2 cytokines IL-4, IL-5, and IL-13
are classically considered the main contributors to the
pathogenesis of AD. It is believed that type 2 inflammation
underlies acute to subacute AD, which manifests histologi-
cally as a combination of irregular acanthosis (epidermal
thickening), spongiosis (interepidermal edema), and superfi-
cial perivascular inflammation in the dermis composed
predominantly of lymphocytes and histiocytes with
occasional neutrophils and eosinophils. Strikingly, ILC2s that
produce IL-5 and IL-13 were found to be both necessary and
sufficient for the development of AD-like disease in a mouse
model (Kim et al., 2013a; Roediger et al., 2013). Further, in
contrast to the previously ascribed roles of IL-25 and/or IL-33
in the gut and lung, proinflammatory skin ILC2s were found to
be dependent on another epithelial cell–derived cytokine
called thymic stromal lymphopoietin (TSLP, Kim et al.,
2013a). Beyond TSLP, a more recent study showed that
transgenic overexpression of IL-33 under a keratin 14 pro-
moter is sufficient to induce AD-like disease in association
with the accumulation of ILC2s (Imai et al., 2013). In addition
to IL-33, Salimi et al. (2013) found that skin ILC2 responses
demonstrate dependence on IL-25, IL-33, and/or TSLP
depending on the mouse strain employed. Taken together,
these studies identified a previously unrecognized role for skin
ILC2s in the development of AD-like disease and their diverse
mechanisms of regulation.
Similar to murine ILC2s, human skin ILC2s express IL-33R
(Kim et al., 2013a) as well as chemoattractant receptor-
homologous molecule expressed on TH2 cells (Salimi et al.,
2013; Xue et al., 2014). Xue et al. (2014) isolated chemo-
attractant receptor-homologous molecule expressed on TH2
cellsþ human skin ILC2s and showed that they migrate
in response to the chemoattractant receptor-homologous
molecule expressed on TH2 cells ligand prostaglandin D2. In
addition, they express skin-homing receptors such as
cutaneous lymphocyte antigen, CCR4, and CCR10 and are
activated by IL-33 to produce the type 2 cytokines IL-5 and
IL-13 (Salimi et al., 2013; Teunissen et al., 2014). In terms of
regulation, Salimi et al. (2013) found that IL-25 or TSLP alone
did not directly activate healthy human skin ILC2s but
significantly potentiated the effects of IL-33. In contrast,
Teunissen et al. (2014) found that TSLP alone was sufficient
to activate expanded skin ILC2s, and this effect was further
enhanced by the addition of IL-25. Therefore, the key
epithelial cell–derived cytokines that regulate human skin
ILC2s remain to be fully clarified in future studies. Notably,
lesional AD skin from patients demonstrated increased expres-
sion of IL-17RB (IL-25R), IL-33R, and TSLP receptor on ILC2s
(Figure 1; Salimi et al., 2013). These findings provoke the
question as to whether activated human skin ILC2s in lesional
AD skin respond differently to IL-25, IL-33, and/or TSLP
compared with ILC2s derived from healthy control skin.
Addressing this question may help distinguish the relative
importance of these cytokines in the context of established
disease and the therapeutic potential of targeting them.
In addition to epithelial cell–derived cytokines, ILC2s are
also activated by IL-2 and express the receptor for IL-7 (IL-7Ra,
CD127), indicating that they also respond to other hematopoi-
etic cell–derived and stromal cytokines (Roediger et al.,
2013). More recently, ILC2s were found to express IL-4Ra
(Bando et al., 2013) and respond to basophil-derived IL-4 by
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Figure 1. Regulation and function of human skin innate lymphoid cells (ILC)
responses. Human skin ILC1s express CD161 and would be predicted to be
activated by IL-12 and IL-15 and produce the effector cytokines TNF-a and
IFN-g. Human skin group 2 ILCs (ILC2s) express KLRG1, cutaneous
lymphocyte antigen (CLA), CCR4, IL-25R (IL-17RB), IL-33R (ST2),
chemoattractant receptor-homologous molecule expressed on TH2 cells
(CRTH2), and thymic stromal lymphopoietin receptor (TSLPR). In response to
IL-25, IL-33, and/or thymic stromal lymphopoietin (TSLP), they produce
effector cytokines IL-5 and IL-13 and have been implicated in atopic dermatitis
(AD). Human skin ILC2s also migrate in response to prostaglandin D2 (PGD2).
Human skin group 3 ILCs (ILC3s) express NKp44 and CLA, produce IL-17 and
IL-22 in response to IL-1b and IL-23, and have been implicated in psoriasis.
BS Kim
ILCs in the Skin
674 Journal of Investigative Dermatology (2015), Volume 135
increasing the production of the chemokine CCL11, as well as
effector cytokines IL-5, IL-9, and IL-13 (Motomura et al., 2014).
Along these lines, we recently identified that basophil-derived
IL-4 critically regulates ILC2 proliferation in the context of AD-
like inflammation (Kim et al., 2014). Taken together, these
studies suggest that a variety of cytokines, chemokines, and/or
lipid mediators can differentially regulate the activation,
migration, proliferation, and effector function of ILC2s.
Beyond cytokine-mediated regulation, E-cadherin has been
found to directly inhibit the effector cytokine production of
human skin ILC2s, possibly via binding cell surface KLRG1
(Salimi et al., 2013). Given that E-cadherin is known to be
downregulated in lesional AD skin (Trautmann et al., 2001),
this may be a key upstream mechanism by which loss of
epithelial adhesion molecules in the context of skin barrier
dysfunction leads to dysregulated ILC2 responses in AD
(Figure 2). Indeed, these studies found that shRNA-mediated
knockdown of filaggrin, a key skin barrier protein that is
diminished in AD, results in loss of E-cadherin expression
(Salimi et al., 2013). Collectively, these studies implicate
ILC2s as a direct link between skin barrier defects and early
immune dysregulation in the skin.
Finally, although skin ILC2s could promote AD-like disease
in the absence of adaptive immunity, they were also sufficient
to drive adaptive TH2 cell responses in vivo (Kim et al.,
2013a). Recent studies show that this can occur indirectly
through the effect of ILC2-derived IL-13 on dendritic cells
(Halim et al., 2014) and/or direct stimulation of T cells via
major histocompatibility complex II (Mirchandani et al.,
2014). Further, ILC2s were visualized in the skin employing
intravital multiphoton microscopy and found to selectively
interact with mast cells in vivo (Roediger et al., 2013).
Employing in vitro assays to monitor mast cell function, it
has been proposed that ILC2s suppress mast cell function via
the production of IL-13 in the steady state. In contrast,
IL-2-mediated activation of ILC2s was sufficient to induce
ILC2-dependent AD-like disease, enhanced production of
IL-5, and the recruitment of eosinophils (Roediger et al.,
2013). Collectively, these studies demonstrated novel regula-
tory and proinflammatory functions of ILC2s in the skin.
ILC3s AND PSORIASIS
CD4þ TH17 cells that produce the effector cytokines IL-17
and IL-22 are classically believed to underlie the pathogenesis
of psoriasis in humans (Nestle et al., 2009). This TH17 cell–
associated cytokine repertoire results in histologic features of
regular acanthosis (uniform elongation of the epidermal rete
ridges), parakeratosis (retention of nuclei in the stratum
corneum), and a neutrophilic inflammatory infiltrate (Zheng
et al., 2007). However, Pantelyushin et al. (2012) employed a
murine model of psoriasis-like disease and found that TH17
cells were not the dominant source of these cytokines but
rather RORgtþ gd T cells and ILC3s. In support of this, they
demonstrated that lymphocyte-deficient mice develop
psoriasiform inflammation in a similar manner to wild-type
mice that harbor TH17 cells. Taken together, these findings
provoked the hypothesis that IL-17- and IL-22-producing ILC3s
may directly contribute to the pathogenesis of psoriasis-like
disease. Indeed, loss-of-function studies employing ILC-
deficient Rag2 / gc
 / mice demonstrated a reduction in
disease severity (Pantelyushin et al., 2012). Collectively, these
studies suggested that ILC3s may actually have a direct role in
psoriasis in humans.
In support of the murine studies by Pantelyushin et al., a
more recent study identified the presence of IL-17- and IL-22-
producing NKp44þ ILC3s in the blood and skin of psoriasis
patients (Villanova et al., 2014). Further investigation revealed
that these NKp44þ ILC3s are highly enriched in both lesional
and non-lesional skin of psoriasis patients in comparison to
healthy control skin. These findings were confirmed by two
separate studies demonstrating increased frequencies of
RORgtþ CD56þ ILC3s that express NKG2D in both lesional
and non-lesional skin of psoriasis patients (Dyring-Andersen
et al., 2014) and NKp44þ ILC3s selectively enriched in
lesional psoriasis skin (Teunissen et al., 2014). In support of
a potential role for ILC3s in the pathogenesis of psoriasis, a
case study in a patient on anti-tumor necrosis factor therapy
(adalimumab) demonstrated correlation between therapeutic
response and a reduction in ILC3s (Villanova et al., 2014).
Further, Teunissen et al. (2014) found that NKp44 ILC3s
convert to NKp44þ ILC3s following stimulation with IL-1b
and IL-23 (Figure 1). Given that disruption of the p40 subunit
of IL-23 is an effective therapy (ustekinumab) for psoriasis,
these findings implicate ILC3s as a potential mechanism by
which IL-23 may mediate disease. Similar to skin ILC2s, ILC3s
were also found to express the skin-homing marker cutaneous
lymphocyte antigen (Villanova et al., 2014) (Figure 1).
Strikingly, cutaneous lymphocyte antigen expression was
much higher on ILC3s in comparison to conventional CD4þ
or CD8þ T cells (Villanova et al., 2014). Collectively,
homologous to ILC2s in AD, these studies highlight a
potential role for skin ILC3s in the pathogenesis of psoriasis.
Prior studies on ILC3s have demonstrated diverse functions
in the intestine ranging from maintenance of epithelial barrier
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Figure 2. Group 2 ILCs (ILC2s) and skin barrier dysfunction. Human skin
ILC2s have been implicated in the pathogenesis of atopic dermatitis (AD) and
are activated by the epithelial cell–derived cytokines IL-25, IL-33, and/or
thymic stromal lymphopoietin (TSLP) to produce IL-5 and IL-13. In contrast, the
keratinocyte cell adhesion molecule E-cadherin has been shown to inhibit the
activation of skin ILC2s, possibly via KLRG1. AD-associated inflammation and
loss of skin barrier protein filaggrin expression are associated with the loss of
E-cadherin expression in keratinocytes.
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function to inflammation and protective immunity to extra-
cellular bacteria (Hepworth and Sonnenberg, 2014).
Furthermore, ILC3s have been found to directly regulate the
function of CD4þ T cells to promote tissue homeostasis in the
intestine (Hepworth et al., 2013). Although ILC3s have been
implicated as proinflammatory cells in psoriasis (Pantelyushin
et al., 2012), whether they interact with adaptive CD4þ
T cells or help maintain tissue homeostasis in the skin
remains to be determined.
ILC1s AND SKIN INFLAMMATION
ILC1s are not as well-defined as the ILC2 and ILC3 subsets. In
addition to conventional NK cells, multiple ILC1-like cells
have been reported. Cytotoxic intestinal intraepithelial
NKp44þ CD103þ (human) and CD160þ NKp46þ NK1.1þ
(murine) ILC1-like cells resemble NK cells but are IL-15-
independent and lack CD127 expression (Fuchs et al., 2013).
More recently, non-cytotoxic T-betþ Eomes CD127þ non-
NK cell ILC1s, which arise from a distinct precursor that does
not give rise to conventional NK cells, but are dependent on
IL-15 for their maintenance and survival, have been reported
(Klose et al., 2014). On the basis of their distinctly non-NK cell
lineage, these cells now appear to be bona fide ILC1s. Further,
T-bet-expressing ‘‘ex-RORgt’’ ILC3s arise from RORgtþ
precursors and can be instructed by IL-12 and/or commensal
microbiota for their differentiation into IFN-g-expressing NK
receptor-expressing ILC1-like cells (Vonarbourg et al., 2010;
Bernink et al., 2013; Klose et al., 2013; Rankin et al., 2013).
Despite these differences, ILC1-like cells and ILC1s are similar
in that all express T-bet and IFN-g (Bernink et al., 2013; Fuchs
et al., 2013; Klose et al., 2013, 2014; Figure 1). They have also
been shown to produce TNF-a and mediate immunity to
intracellular infections with Toxoplasma gondii and Salmo-
nella (Klose et al., 2013, 2014). In addition, human ILC1s are
associated with Crohn’s disease (Bernink et al., 2013; Fuchs
et al., 2013), and their murine counterpart has been shown to
contribute to the development of experimental colitis (Fuchs
et al., 2013). Although chemoattractant receptor-homologous
molecule expressed on TH2 cells
 c-Kit NKp44 CD161þ
ILC1s have been identified in human skin as a rare population
(Teunissen et al., 2014; Villanova et al., 2014), their function
in skin disease remains unknown and is an exciting area of
future inquiry. Recent studies have demonstrated that allergic
contact dermatitis can exhibit mixed TH cell responses
(Dhingra et al., 2014) in addition to classical TH1 cytokine
responses ( Kehren et al., 1999; Gorbachev et al., 2001;Saint-
Mezard et al., 2005; Ishizaki et al., 2007). Similarly, based on
the recent studies with ILC2s and ILC3s, it is possible that skin
ILC1s may also contribute to the development of allergic
contact dermatitis.
CONCLUSIONS
The mammalian immune system has evolved a sophisticated
array of adaptive immune responses to ward off invading
microbial pathogens at the skin barrier. Specifically, adaptive
immune cells such as T cells can recognize and combat
infections in a specialized manner by recognizing specific
antigens encountered over time. In addition, recent studies
have also demonstrated that adaptive T cells also limit the
translocation of skin commensal bacteria into the
lymphatic system (Shen et al., 2014). However, it is widely
appreciated that inappropriate immune responses in the skin
against environmental allergens or self-antigens can result in
the development of a variety of inflammatory skin disorders.
Therefore, interventions for diseases such as AD and psoriasis
have classically attempted to target adaptive T cells.
The identification of different ILC populations that are
resident at the skin barrier indicates that these cells may have
evolved to respond immediately to pathogenic signals and to
aid the adaptive immune system in mounting a robust immune
response. The studies outlined in this review highlight that
dysregulation of ILCs can result in the development of multiple
inflammatory skin diseases. Although commensal microbiota
in the gut are known to interact with ILC1-like cells
(Vonarbourg et al., 2010; Klose et al., 2013) and ILC3s
(Sonnenberg et al., 2012; Hepworth et al., 2013; Qiu et al.,
2013), their interactions with ILC2s and their role in skin
barrier homeostasis are less well defined. It would be expected
that innate signals from skin commensal microbiota are
required to maintain normal frequencies and functions of
skin ILCs, and this remains an exciting area of future
investigation. More broadly, how ILCs are regulated in the
skin, the array of effector mechanisms they employ, and their
potential role in maintaining skin barrier homeostasis remains
unclear. Inflammatory skin diseases are the most common
conditions affecting the skin, and it is possible that ILCs will
have critical roles in a variety of disease states including, but
not limited to, allergic contact dermatitis, bullous pemphigoid,
arthropod bites, and Sweet’s syndrome. On the basis of the
histopathology of these disease states, it can be hypothesized
which ILC subsets (e.g., ILC2s for eosinophilic or ILC3s for
neutrophilic inflammation) may have a role in their patho-
genesis. To improve our understanding of the function of skin
ILCs, further investigation is necessary to (i) understand the
contributions of ILC populations to different disease states, (ii)
examine how ILCs regulate skin homeostasis, and (iii) identify
novel ILC-specific markers for therapeutic intervention.
Studying the mechanisms that maintain skin immune home-
ostasis in health and disease may identify new therapeutic
targets for the treatment of numerous chronic inflammatory
skin diseases.
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